Sulfated alginate based complex for sustained calcitonin delivery and enhanced osteogenesis

Direct medications of salmon calcitonin (sCT) through subcutaneous or intramuscular injection are limited for its low effeciency. Drug delivery systems with sustained delivery property and high bioactivity are imminently needed. In consideration of the clinic application, a cost-effective and effective carrier is demanded, which is still a challenge until now. In this study, a simple alginate/ alginate sulfate-sCT (Alg/AlgS-sCT) complex was succesfully constructed for sustained release of sCT. The negtively charged sulphate groups facilitate the bonding with sCT, which avoids the burst release of sCT and extends the release time up to 15 days (only 2 days for pure sCT). More importantly, the bioactivity of the released sCT is not affected during such long release time, suggesting a conformation similar to native sCT. In vitro analysis implies the biocompatibility of the complex. Moreover, the combination of AlgS and sCT synergistically impoved the osteogenic ability of MC3T3 cells, showing higher ALP level, intracellular and extracellular calcium ions concentrations. Note that the concentration of intracellular calcium ions displays 5.26 fold increments of control group after 10 days of incubation. We envision this simple yet effective system has potential applications in clinical trails and give inspiration for the design of other protein delivery system.

Sustained release of dermal papilla-derived extracellular vesicles from injectable microgel promotes hair growth

Hair regeneration has long captured researchers' attention because alopecia is a common condition and current therapeutic approaches have significant limitations. Dermal papilla (DP) cells serve as a signaling center in hair follicles and regulate hair formation and cycling by paracrine secretion. Secreted EVs are important signaling mediators for intercellular communication, and DP-derived extracellular vesicles (DP-EVs) may play an important role in hair regeneration. However, the instability of EVs in vivo and their low long-term retention after transplantation hinder their use in clinical applications.

Methods: Human DP-EVs were encapsulated in partially oxidized sodium alginate (OSA) hydrogels, yielding OSA-encapsulated EVs (OSA-EVs), which act as a sustained-release system to increase the potential therapeutic effect of DP-EVs. The ability of the OSA-EVs to protect protein was assessed. The hair regeneration capacity of OSA-EVs, as well as the underlying mechanism, was explored in hair organ culture and a mouse model of depilation.

Results: The OSA-EVs were approximately 100 μm in diameter, and as the hydrogel degraded, DP-EVs were gradually released. In addition, the hydrogel markedly increased the stability of vesicular proteins and increased the retention of EVs in vitro and in vivo. The OSA-EVs significantly facilitated proliferation of hair matrix cells, prolonged anagen phase in cultured human hairs, and accelerated the regrowth of back hair in mice after depilation. These effects may be due to upregulation of hair growth-promoting signaling molecules such as Wnt3a and β-catenin, and downregulation of inhibitory molecule BMP2.

Conclusion: This study demonstrated that OSA hydrogels promote the therapeutic effects of DP-EVs, and indicate that our novel OSA-EVs could be used to treat alopecia.

In vitro degradation and drug-release properties of water-soluble chitosan cross-linked oxidized sodium alginate core-shell microgels

Hydrogels based on sodium alginate (SA) have already been widely used in biomedical applications using Ca(2+) as a cross-linker; however, these hydrogels tend to disintegrate in electrolyte solutions. To solve this problem, we present a kind of oxidized sodium alginate (OSA) microgel using water-soluble chitosan (WSC) as a cross-linker. This microgel was successfully prepared via an emulsion cross-linking technique at room temperature. The microgel was cross-linked by the formation of both Schiff base bonds and inter-polyelectrolyte complexes, which can efficiently eliminate the disintegration of the microgel in electrolyte solutions. Morphological properties of the resulting microgels were determined by transmission electron microscopy (TEM), hydrodynamic diameters of the microgels were characterized by dynamic light scattering (DLS). The objective of this work was to achieve the colon-specific delivery of an anti-ulcerative colitis drug. 5-Aminosalicylic acid (5-ASA) was chosen as a model drug and the in vitro drug-release profile was established in buffer solutions with 0.1 M HCl/NaCl (pH 1.2) and 0.1 M phosphate-buffered saline (PBS, pH 7.4) at 37°C. The microgel was incubated in 0.1 M PBS (pH 7.4) at 37°C to determine its degradation behavior. Cell cytotoxicity (tested by MTT assay) showed that this microgel had no significant cytotoxicity. These results indicated that this microgel prepared by introducing WSC into OSA may have potential applications in oral controlled drug-delivery systems. Therefore, the OSA/WSC microgel may be a useful carrier for the colon-specific delivery of anti-inflammatory drugs including 5-ASA and the enhanced therapeutic effect of ulcerative colitis.